Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-21-328059
Filing Date
2021-11-12
Accepted
2021-11-12 16:06:15
Documents
16
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d258219d10ka.htm   iXBRL 10-K/A 37333
2 EX-31.1 d258219dex311.htm EX-31.1 11187
3 EX-31.2 d258219dex312.htm EX-31.2 11193
  Complete submission text file 0001193125-21-328059.txt   242803

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alna-20201231.xsd EX-101.SCH 4686
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20201231_cal.xml EX-101.CAL 684
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20201231_def.xml EX-101.DEF 1689
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20201231_lab.xml EX-101.LAB 20586
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20201231_pre.xml EX-101.PRE 16535
9 EXTRACTED XBRL INSTANCE DOCUMENT d258219d10ka_htm.xml XML 6571
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

EIN.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38268 | Film No.: 211403410
SIC: 2836 Biological Products, (No Diagnostic Substances)